Skip to main content
Clinical Trials/NCT05406752
NCT05406752
Completed
Phase 1

An Open-label, Single Treatment, Single Period, Single Buccal Dose Pharmacokinetic Study of Paracetamol Uniflash (125 mg/ 1.25 mL) in Healthy, Adult, Human Subjects Under Fasting Conditions.

Unither Pharmaceuticals, France1 site in 1 country32 target enrollmentJuly 22, 2022

Overview

Phase
Phase 1
Intervention
paracetamol Uniflash (125 mg/ 1.25 mL)
Conditions
Acute Pain
Sponsor
Unither Pharmaceuticals, France
Enrollment
32
Locations
1
Primary Endpoint
Paracetamol Peak Plasma Concentration (Cmax) After Single Dose
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study aims to assess the pharmacokinetic profile of a new paracetamol formulation (paracetamol Uniflash 125mg/1.25mL) for buccal use after single dose.

Registry
clinicaltrials.gov
Start Date
July 22, 2022
End Date
July 23, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Unither Pharmaceuticals, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male and non-pregnant female human subjects, age 18 - 45 years.
  • Body Mass Index between 18.5-30 Kg / m2 .
  • Subjects with normal findings .
  • Willingness to follow the protocol requirements

Exclusion Criteria

  • History of allergy or hypersensitivity intolerance to paracetamol and ethanol
  • Significant history or current evidence of malignancy or chronic - infectious, cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic (endocrine), hematological, gastrointestinal, dermatological, immunological or psychiatric diseases, or organ dysfunction;
  • Lactating or nursing female subjects;
  • History of difficulty in accessibility of veins in arms.

Arms & Interventions

paracetamol Uniflash (125 mg/ 1.25 mL)

1 sachet of paracetamol Uniflash 125mg / 1.25 mL

Intervention: paracetamol Uniflash (125 mg/ 1.25 mL)

Outcomes

Primary Outcomes

Paracetamol Peak Plasma Concentration (Cmax) After Single Dose

Time Frame: Up to 12 hours post dose

Peak Plasma Concentration (Cmax) of paracetamol after single dose at different timepoints : Within 60 min before drug administration), at 1 min, 5 min, 10 min, 15 min, 20 min, 40 min, 1h, 2h, 4h, 6h, 8h, 10h and 12h post-dose

Paracetamol Area Under the Plasma Concentration Versus Time Curve (AUC) After Single Dose

Time Frame: Up to 12 hours post dose

Area under the plasma concentration versus time curve (AUC) of paracetamol after single dose at different timepoints :Within 60 min before drug administration), at 1 min, 5 min, 10 min, 15 min, 20 min, 40 min, 1h, 2h, 4h, 6h, 8h, 10h and 12h post-dose

Secondary Outcomes

  • Number of Treatment-related Adverse Events(Up to 12 hours)

Study Sites (1)

Loading locations...

Similar Trials